Market Overview
The allergy diagnostics and therapeutics market represents a substantial segment of the global healthcare industry, driven by the increasing global burden of allergic diseases across all age groups. The market is valued at approximately $36.84 billion in 2025 and is projected to continue expanding through 2030, with various analyses suggesting the market could approach $60-75 billion by 2034-2035 depending on methodology and regional scope.
- •The market includes diagnostic tools such as skin prick tests, blood tests, and patch tests alongside therapeutic interventions including immunotherapy and biologics
- •Food allergy diagnostics represent one of the fastest-growing segments as awareness and screening protocols expand globally
- •Technological innovations in molecular diagnostics and component-resolved diagnostics are reshaping traditional allergy testing approaches
Growth Drivers
Several fundamental factors are propelling market expansion, including the rising global prevalence of allergic conditions attributed to environmental changes, urbanization, and dietary shifts. Advances in diagnostic accuracy and the introduction of targeted biologic therapies are creating new treatment paradigms that drive both diagnostic and therapeutic demand.
- •Increasing pollution levels, climate change effects on pollen seasons, and changing lifestyle patterns contribute to higher allergy incidence rates
- •Growing healthcare expenditure in emerging markets and expanded insurance coverage for allergy treatments
- •Development of precision medicine approaches and personalized allergy therapies is creating higher-value market segments
Segmentation and Regional Analysis
The market is typically segmented by product type, allergy type, end-user, and geography, with diagnostic testing currently representing a larger share than therapeutics but with therapeutics growing faster. Regional dynamics show North America and Europe dominating current market share, while Asia-Pacific is emerging as the fastest-growing region due to rising healthcare infrastructure and increasing disease burden.
- •Diagnostics segment includes allergen-specific IgE testing, skin allergy tests, and food intolerance testing
- •Therapeutics segment encompasses immunotherapy drugs, antihistamines, corticosteroids, and biologics targeting specific immune pathways
- •Hospital laboratories, diagnostic centers, and research institutions constitute the primary end-user categories
Trends and Outlook
What are the recent trends and outlook?
The market is moving toward integrated diagnostic-therapeutic solutions and digital health applications, with telemedicine platforms beginning to incorporate allergy screening workflows. Future growth will likely be sustained by molecular diagnostics advancements, microbiome research informing new therapeutic approaches, and the expansion of allergy awareness programs in developing nations.
- •Artificial intelligence and machine learning applications are being integrated into allergy diagnostics for improved pattern recognition and predictive capabilities
- •Emerging therapies targeting novel immune pathways, including biologics and oral immunotherapy, are expected to drive therapeutic segment growth
- •Point-of-care allergy testing and at-home diagnostic kits represent growing opportunities as consumer healthcare preferences evolve
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.